Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.

Part 1 (n = 36) established a recommended belamaf phase 2 dose (RP2D) of 1.9 mg/kg every 8 weeks (median follow-up, 39.3 months).

第一部分（n = 36）确定了belamaf 2期推荐剂量（RP2D）为每8周1.9 mg/kg（中位随访期为39.3个月）。

In part 2, 30 patients were randomized 1:1 in group A (n = 15), where belamaf dosing was guided by ophthalmologist-assessed ocular adverse events (OAEs), whereas in group B (n = 15), belamaf dosing was based on hematologist-led vision-related anamnestic (VRA) tool and ophthalmologist-assessed grade ≥3 OAEs.

在第二部分中，30名患者按1:1的比例随机分为A组（n = 15），其中belamaf剂量由眼科医生评估的眼科不良事件（OAEs）指导，而在B组（n = 15），belamaf剂量基于血液科医生主导的视力相关记忆（VRA）工具和眼科医生评估的3级或以上OAEs。

Among the RP2D patients (n = 42), overall response rate was 97.6%, median progression-free survival(PFS)/overall survivalhave not been reached yet, and the 18-month PFS and time to progression rates were 83.0% and 97.2%, respectively.

在RP2D患者中（n = 42），总缓解率为97.6%，中位无进展生存期（PFS）/总生存期尚未达到，18个月的PFS和疾病进展时间分别为83.0%和97.2%。

Ocular toxicities were similar between assessments by hematologists and ophthalmologists, and no ophthalmologist withholding of a hematologist-led dosing occurred.

眼科毒性在血液科医生和眼科医生的评估中相似，没有眼科医生在血液科医生指导下停药的情况。

Less than 1% of patients stopped driving/reading because of OAEs.

不到1%的患者因眼部不良事件(OAEs)停止驾驶/阅读。

Median time to belamaf reinfusion was 13 weeks.

belamaf回输的中位时间是13周。

Overall, BelaRd is an effective regimen for transplant-ineligible patients with NDMM and warrants a phase 3 study in this setting.

总的来说，BelaRd方案对于不适合移植的NDMM患者是有效的，并且在这个背景下值得进行III期研究。

OAEs' impact on quality of life appears limited, and implementation of the hematologist-led VRA tool may eventually reduce the necessity for ophthalmologist assessments.

OAEs对生活质量的影响似乎有限，实施血液科医生主导的VRA工具最终可能会减少眼科医生评估的必要性。

This trial was registered at www.clinicaltrials.gov as #NCT04808037.

这项试验已在www.clinicaltrials.gov上注册，注册号为#NCT04808037。